Shots:

• The P-III RELIEF study evaluating the efficacy and safety of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) vs PBO in patients for the management of fibromyalgia. The first 2 wks treatment start on TNX-102 SL (2.8 mg) or PBO and after that the dose increased to TNX-102 SL (5.6 mg) or 2 PBO for 12 wks
• The trial met its 1EPs i.e TNX-102 SL (5mg) showed a reduction in daily pain with a higher rate of ≥30% pain responders. The 2EPs include improvements in sleep quality- mitigation of fatigue- and fibromyalgia-specific functional recovery- and were well tolerated
• The interim analysis results for the P-III RALLY study is expected in Q3’21

Ref: Globe Newswire | Image: Tonix